clodronic acid has been researched along with Cancer of Prostate in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.77) | 18.7374 |
| 1990's | 21 (32.31) | 18.2507 |
| 2000's | 26 (40.00) | 29.6817 |
| 2010's | 10 (15.38) | 24.3611 |
| 2020's | 1 (1.54) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Chen, W; Huang, X; Jiang, H; Lin, R; Wu, C; Wu, J; Zhang, X; Zhu, B | 1 |
| Chen, H; Chen, W; Duan, F; Jin, H; Li, C; Liu, Q; Mo, L; Wang, F; Weng, Z; Yu, Z | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Hering, F; Imperio, M; Rodrigues, P | 1 |
| Gravis, G; Salem, N; Walz, J | 1 |
| Cho, SW; Daignault-Newton, S; Entezami, P; Jones, JD; Kim, YW; Koh, AJ; McCauley, LK; Park, SI; Pienta, KJ; Roca, H; Soki, FN | 1 |
| Bergh, A; Halin, S; Rudolfsson, SH; Van Rooijen, N | 1 |
| Dearnaley, DP; Mason, MD; Parmar, MK; Sanders, K; Sydes, MR | 1 |
| Aragon-Ching, JB | 1 |
| Lipton, A; Saad, F | 1 |
| Choi, HJ; Fan, D; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Kim, SW; Langley, RR; Maya, M; Papadopoulos, J | 1 |
| Morgan, GJ | 1 |
| Morgans, AK; Smith, MR | 1 |
| Barthel, HR | 1 |
| Cook, R; Major, PP | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW | 1 |
| Saad, F | 1 |
| Bankhead, C | 1 |
| Dearnaley, DP; Mason, MD; Moffat, LE; Naylor, SL; Parmar, MK; Powell, CS; Robinson, AC; Stott, M; Sydes, MR; Thompson, PM | 1 |
| Smith, MR | 1 |
| Hershman, D; Narayanan, R | 1 |
| Campagnari, JC; Hering, F; Rodrigues, P | 1 |
| Kamby, C; Kristensen, B; Pedersen, L | 1 |
| Altan, A; Demir, C; Ozyuvaci, E | 1 |
| Parker, CC | 1 |
| Dahut, WL; Gulley, J | 1 |
| Afonso, Y; Bruna, P; Hering, FO; Meller, A; Rodrigues, P | 1 |
| Dearnaley, DP; Glaholm, J; Huddart, RA; James, ND; Langley, RE; Mason, MD; Parmar, MK; Robinson, AC; Sokal, M; Stott, M; Sydes, MR | 1 |
| Body, JJ; Brown, JE; Cameron, DA; Coleman, RE; Dewar, JA; Harnett, AN; McCloskey, EV; Purohit, OP; Ruutu, M; Tähtelä, R | 1 |
| Vorreuther, R | 1 |
| Kylmälä, T; Lindholm, TS; Seppänen, J; Tammela, TL | 1 |
| Cresswell, SM; English, PJ; Hall, RR; Marsh, MM; Roberts, JT | 1 |
| Elomaa, I; Kylmälä, T; Risteli, J; Risteli, L; Tammela, T; Taube, T | 1 |
| Elomaa, I; Kylmälä, T; Lamberg-Allardt, C; Tammela, TL; Taube, T | 1 |
| Dearnaley, DP; Glaholm, J; Mason, MD | 1 |
| Mayordomo, JI; Rivera, F | 1 |
| Castrén-Kortekangas, P; Kylmälä, T; Seppänen, J; Tammela, TL; Ylitalo, P | 1 |
| Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S | 1 |
| Elomaa, I; Kylmälä, T; Risteli, J; Risteli, L; Tammela, TL; Taube, T | 1 |
| Aaron, JE; Alcover, J; Carretero, P; Fernández-Conde, M; Ordi, J | 1 |
| Adami, S | 1 |
| Heidenreich, A | 1 |
| Bloomfield, DJ | 1 |
| Kylmälä, T | 1 |
| Englund, G; Larsson, B; Larsson, L; Magnusson, P; Selin-Sjögren, L; Strang, P | 1 |
| Berthaud, P; Jadaud, E; Lortholary, A | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Engelmann, UH; Heidenreich, A; Hofmann, R | 1 |
| Jones, J | 1 |
| Hamdy, NA; Pelger, RC; Soerdjbalie-Maikoe, V | 1 |
| Härkönen, PL; Lakkakorpi, PT; Väänänen, HK; Virtanen, SS | 1 |
| Engelking, R; Klotz, T; Vorreuther, R | 1 |
| Ala-Opas, M; Elomaa, I; Jauhiainen, K; Kylmälä, T; Ottelin, J; Roos, L; Ruutu, M; Seppänen, J; Tammela, T; Viitanen, J | 1 |
| Geldof, AA; Newling, DW; Rao, BR; Sun, YC | 1 |
| Beuzeboc, P; Pouillart, P | 1 |
| Adami, S; Mian, M | 1 |
| Adami, S; Bianchi, G; Dorizzi, R; Guarrera, G; Lo Cascio, V; Mobilio, G; Rosini, S; Salvagno, G | 1 |
| Luckert, PH; Pollard, M | 2 |
| Pollard, M; Tazume, S | 1 |
| Luckert, PH; Pollard, M; Scheu, J | 1 |
| Kanis, JA; Percival, RC; Watson, ME; Williams, JL | 1 |
19 review(s) available for clodronic acid and Cancer of Prostate
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.
Topics: Bone Density; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Clodronic Acid; Fractures, Bone; Humans; Male; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2019 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
[Metastatic hormone-sensitive prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Combined Modality Therapy; Docetaxel; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids | 2015 |
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Peptides; Prognosis; Prostatic Neoplasms; RANK Ligand; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2010 |
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome; Zoledronic Acid | 2011 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid | 2012 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
Topics: Analgesics, Non-Narcotic; Antimetabolites; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
[Diphosphonates in solid malignant tumors].
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms | 2005 |
The role of bisphosphonates in the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Clinical Trials, Phase III as Topic; Clodronic Acid; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Clodronate in the prevention and treatment of skeletal metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Dose-Response Relationship, Drug; Female; Humans; Male; Morbidity; Prostatic Neoplasms; Risk Factors | 2005 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Male; Neoplasm Invasiveness; Osteoclasts; Pain; Prostatic Neoplasms | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence-Based Medicine; Female; Humans; Male; Multiple Myeloma; Pain; Pamidronate; Practice Guidelines as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Male; Multiple Myeloma; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Strategies for management of prostate cancer-related bone pain.
Topics: Analgesics; Animals; Bone Neoplasms; Clodronic Acid; Humans; Male; Pain; Pain Management; Prostatic Neoplasms; Radioisotopes | 2001 |
19 trial(s) available for clodronic acid and Cancer of Prostate
| Article | Year |
|---|---|
Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.
Topics: Aged; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2013 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Regression Analysis; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Topics: Administration, Oral; Aged; Analgesics, Non-Narcotic; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Digestive System; Diphosphonates; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Odds Ratio; Pain; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid | 2003 |
[The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Topics: Administration, Oral; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pain, Intractable; Prostatic Neoplasms; Treatment Outcome | 2005 |
Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).
Topics: Administration, Oral; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Clodronic Acid; Combined Modality Therapy; Disease Progression; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy | 2007 |
The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Peptide Fragments; Placebos; Predictive Value of Tests; Procollagen; Prostatic Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2007 |
Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate.
Topics: Aged; Bone Neoplasms; Clodronic Acid; Humans; Male; Pain; Palliative Care; Pilot Projects; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1993 |
Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Clodronic Acid; Collagen; Estramustine; Humans; Male; Middle Aged; Pain; Palliative Care; Peptide Fragments; Procollagen; Prostatic Neoplasms | 1993 |
The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Bone Resorption; Clodronic Acid; Double-Blind Method; Humans; Male; Middle Aged; Osteogenesis; Osteomalacia; Prostatic Neoplasms | 1994 |
Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analysis of Variance; Antineoplastic Agents, Hormonal; Biological Availability; Bone Neoplasms; Carcinoma; Clodronic Acid; Drug Synergism; Drug Therapy, Combination; Estramustine; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1996 |
Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Collagen; Double-Blind Method; Humans; Injections, Intravenous; Male; Middle Aged; Pain; Peptide Fragments; Procollagen; Prospective Studies; Prostatic Neoplasms | 1997 |
Skeletal response to clodronate in prostate cancer with bone metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Bone and Bones; Bone Matrix; Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Clodronic Acid; Disease Progression; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Injections, Intravenous; Male; Middle Aged; Orchiectomy; Osteoblasts; Osteoclasts; Palliative Care; Prostatic Neoplasms; Quality of Life | 1997 |
[Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
Topics: Analgesics, Non-Narcotic; Antibiotics, Antineoplastic; Bone Neoplasms; Clodronic Acid; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms | 1997 |
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analgesics, Non-Narcotic; Biomarkers, Tumor; Bone and Bones; Bone Neoplasms; Clodronic Acid; Collagen; Collagen Type I; Double-Blind Method; Humans; Isoenzymes; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteocalcin; Pain, Intractable; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms | 1998 |
The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Topics: Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Karnofsky Performance Status; Male; Pain; Pain Measurement; Palliative Care; Prospective Studies; Prostatic Neoplasms; Time Factors | 2001 |
[Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
Topics: Aged; Bone Neoplasms; Carcinoma; Clodronic Acid; Combined Modality Therapy; Humans; Male; Palliative Care; Pilot Projects; Prospective Studies; Prostatic Neoplasms | 1992 |
Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
Topics: Administration, Oral; Aged; Analgesics; Bone Neoplasms; Calcium; Clodronic Acid; Estramustine; Humans; Male; Pain; Prostatic Neoplasms | 1992 |
Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Clodronic Acid; Diphosphonates; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intramuscular; Male; Multicenter Studies as Topic; Pain; Prostatic Neoplasms; Random Allocation | 1989 |
27 other study(ies) available for clodronic acid and Cancer of Prostate
| Article | Year |
|---|---|
Safety of I.V. Nonnitrogen bisphosphonates on the occurrence of osteonecrosis of the jaw: long-term follow-up on prostate cancer patients.
Topics: Administration, Intravenous; Aged; Androgen Antagonists; Bisphosphonate-Associated Osteonecrosis of the Jaw; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2015 |
Bone marrow macrophages support prostate cancer growth in bone.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Regeneration; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Clodronic Acid; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Prostatic Neoplasms; Receptor, Macrophage Colony-Stimulating Factor; Tumor Burden | 2015 |
Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.
Topics: Angiogenic Proteins; Animals; Cell Proliferation; Chemokines; Clodronic Acid; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Liposomes; Macrophages; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2009 |
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Follow-Up Studies; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Further analysis of the survival benefit of clodronate.
Topics: Bone Density Conservation Agents; Clodronic Acid; Humans; Male; Prognosis; Prostatic Neoplasms | 2009 |
Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.
Topics: Animals; Bone Neoplasms; Carcinoma; Cell Communication; Cell Line, Tumor; Clodronic Acid; Humans; Interleukin-6; Liposomes; Macrophages; Male; Mice; Mice, Nude; Osteoclasts; Prostatic Neoplasms; RNA, Small Interfering; Tumor Burden; Tumor Necrosis Factor-alpha | 2011 |
Bisphosphonates for RSDS and prostate cancer--more benefit then revealed!
Topics: Analgesics, Non-Narcotic; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Humans; Male; Pamidronate; Prostatic Neoplasms; Reflex Sympathetic Dystrophy; Treatment Outcome | 2002 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid | 2003 |
Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Palliative Care; Prospective Studies; Prostatic Neoplasms; Time Factors | 2004 |
The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Clodronic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hydroxyproline; Infusions, Intravenous; Male; Middle Aged; Pain Measurement; Palliative Care; Prostatic Neoplasms | 1994 |
Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Bone Neoplasms; Clodronic Acid; Drug Resistance; Humans; Infusions, Intravenous; Male; Pain; Pain Measurement; Palliative Care; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 1995 |
The use of bisphosphonates in prostatic cancer.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Male; Prostatic Neoplasms | 1994 |
Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside.
Topics: Administration, Oral; Amikacin; Clodronic Acid; Drug Therapy, Combination; Humans; Hypocalcemia; Male; Prostatic Neoplasms | 1993 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured | 1997 |
Prostate cancer and bone metastases. The effect of clodronate.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Development; Bone Neoplasms; Bone Resorption; Clodronic Acid; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1998 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Bisphosphonates may be useful in treatment of bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Male; Pamidronate; Prostatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Topics: Alendronate; Antimetabolites; Bone Neoplasms; Cell Movement; Clodronic Acid; Dose-Response Relationship, Drug; Humans; Male; Mevalonic Acid; Neoplasm Invasiveness; Prostatic Neoplasms; Tumor Cells, Cultured | 2002 |
Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates.
Topics: Animals; Bone Neoplasms; Clodronic Acid; Diphosphonates; Male; Pamidronate; Prostatic Neoplasms; Rats; Time Factors; Tumor Cells, Cultured | 1992 |
[Value of Clodronate in the treatment of bone metastasis].
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Female; Humans; Hypercalcemia; Male; Osteolysis; Prostatic Neoplasms | 1991 |
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Male; Middle Aged; Pain; Prostatic Neoplasms | 1985 |
Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Bone and Bones; Bone Resorption; Clodronic Acid; Diphosphonates; Male; Neoplasm Metastasis; Osteolysis; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1985 |
The relationship between natural killer cells and drugs that modify metastasis of PA-III cells.
Topics: Adenocarcinoma; Animals; Cell Line; Clodronic Acid; Female; Killer Cells, Natural; Male; Neoplasm Metastasis; Piroxicam; Prostaglandins; Prostatic Neoplasms; Rats; Thiazines | 1985 |
The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells.
Topics: Adenocarcinoma; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Female; Humans; Male; Neoplasm Transplantation; Osteolysis; Piroxicam; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Thiazines | 1986 |
Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells.
Topics: Adenocarcinoma; Animals; Clodronic Acid; Diphosphonates; Female; Male; Neoplasm Transplantation; Osteoblasts; Osteoclasts; Osteolysis; Osteolysis, Essential; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Scapula; Transplantation, Heterologous; Tumor Cells, Cultured | 1988 |
Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption.
Topics: Aged; Bone Neoplasms; Bone Resorption; Clodronic Acid; Drug Therapy, Combination; Humans; Male; Osteitis Deformans; Paralysis; Plicamycin; Prostatic Neoplasms | 1985 |